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Abstract Sustained exposure to high levels of parathyroid
hormone (PTH), as observed in hyperparathyroidism, is
catabolic to bone. The increase in the RANKL/OPG ratio
in response to continuous PTH, resulting in increased
osteoclastogenesis, is well established. However, the
effects of prolonged PTH exposure on key regulators of
skeletal mineralisation have yet to be investigated. This
study sought to examine the temporal expression of
PHOSPHO1, TNAP and nSMase2 in mineralising osteo-
blast-like cell cultures and to investigate the effects of
continuous PTH exposure on the expression of these
enzymes in vitro. PHOSPHO1, nSMase2 and TNAP
expression in cultured MC3T3-C14 cells significantly
increased from day 0 to day 10. PTH induced a rapid
downregulation of Phospho1 and Smpd3 gene expression
in MC3T3-C14 cells and cultured hemi-calvariae. Alpl was
differentially regulated by PTH, displaying upregulation in
cultured MC3T3-C14 cells and downregulation in hemi-
calvariae. PTH was also able to abolish the stimulatory
effects of bone morphogenic protein 2 (BMP-2) on Smpd3
and Phospho1 expression. The effects of PTH on Phospho1
expression were mimicked with the cAMP agonist for-
skolin and blocked by the PKA inhibitor PKI (5-24),
highlighting a role for the cAMP/PKA pathway in this
regulation. The potent down-regulation of Phospho1 and
Smpd3 in osteoblasts in response to continuous PTH may
provide a novel explanation for the catabolic effects on the
skeleton of such an exposure. Furthermore, our findings
support the hypothesis that PHOSPHO1, nSMase2 and
TNAP function cooperatively in the initiation of skeletal
mineralisation.
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Introduction
Phosphatases are essential regulators of skeletal minerali-
sation, modifying local levels of inorganic phosphate (Pi),
inorganic pyrophosphate (PPi) and the phosphorylation
status of osteopontin, a key regulator of extracellular
matrix (ECM) mineralisation [1]. The importance of tissue-
nonspecific alkaline phosphatase (TNAP) as an essential
component of successful skeletal mineralisation is perhaps
most striking in the condition known as hypophosphatasia
(HPP). Individuals possessing hypomorphic ALPL (the
gene encoding TNAP in humans) mutations typically pre-
sent with severe rickets and osteomalacia resulting in a
blockade of hydroxyapatite propagation within the ECM
[2]. Despite this, chondrocyte- and osteoblast-derived
matrix vesicles (MV) from both HPP patients and Alpl-/-
mice retain the ability to initiate intra-vesicular minerali-
sation and contain hydroxyapatite crystals [3, 4], high-
lighting that TNAP is not essential for the initiation of MV-
mediated ECM mineralisation.
Active within chondrocyte- and osteoblast-derived MV
[5, 6] and expressed exclusively in mineralising bone,
cartilage and dentin [7–9], PHOSPHO1, a member of the
haloacid dehalogenase superfamily, is essential for the
initiation of MV-mediated mineralisation. Small-molecule
inhibition of PHOSPHO1 in MV’s derived from Alpl-/-
mice significantly affects their ability to calcify in vitro [7].
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The genetic ablation of Phospho1 results in severely
hypomineralised skeletal and dental tissues with resulting
bowing of the long bones, spontaneous fractures and sco-
liosis [9–12]. Complete ablation of skeletal mineralisation
is observed in Phospho1-/-;Alpl-/- double-knockout
embryos and in metatarsals cultured in the presence of both
PHOSPHO1 and TNAP inhibitors [11, 13]. In vitro,
PHOSPHO1 shows high phosphohydrolase activity
towards phosphocholine and phosphoethanolamine, two
metabolites derived from lipid metabolism [5]. More
recently, hypomineralisation of skeletal and dental tissues
was observed in the fro/fro mouse, a mouse containing a
major deletion in the sphingomyelinase phosphodiesterase
3 (Smpd3) gene [14, 15]. Smpd3 encodes for neutral sph-
ingomyelinase 2 (nSMase2), which catalyses the break-
down of the membrane lipid sphingomyelin to ceramide
and phosphocholine. Through their role in the generation
and processing of phosphocholine, nSMase2 and PHOS-
PHO1, respectively, may function together to liberate Pi
for skeletal mineralisation. In spite of our knowledge of the
skeletal pathophysiology in the absence of Phospho1, little
is known about the regulation of Phospho1 expression.
A recent RNA-seq analysis by St John et al. [16]
revealed that Phospho1 and Smpd3 expression are differ-
entially regulated by parathyroid hormone (PTH) treatment
of IDG-SW3 cells (an osteocyte cell line). This study
extends a growing body of evidence revealing that PTH
can regulate a plethora of genes involved in osteoblast
function [17]. Indeed, a microarray study of PTH-treated
UMR-106-01 cells, a rat osteosarcoma cell line, revealed
[100 differentially regulated genes, with the gene profile
closely mimicking the gene expression pattern observed
during osteoblast differentiation [18]. The transcription and
posttranslational modification (phosphorylation) of Cbfa1,
the transcription factor and master regulator of osteoblast
differentiation are also strongly enhanced by PTH [19].
Alterations in osteoblast gene expression by PTH may
underscore PTH ability to elicit both anabolic and catabolic
effects on the skeleton depending on the duration of the
exposure. For example, daily injections of low-dose PTH
are anabolic to the skeleton, whereas continuous exposure
to PTH, the likes observed in hyperparathyroidism, results
in bone loss and increased porosity especially in the cor-
tical compartment [20]. Indeed, despite an overall increase
in bone remodelling [21], the enhancement of receptor
activator of nuclear factor-jB ligand (RANKL) expression
and thus osteoclastogenesis, and the suppression of the
RANKL decoy receptor, osteoprotegerin [22], ensure that
any increases in bone formation are outweighed by a pre-
vailing bone resorption response. Furthermore, the bone
formation response that occurs is predominated by osteoid
production rather than a true mineralised bone matrix [23].
The reduction in bone mineral density associated with
hyperparathyroidism [24] may be a direct effect of PTH on
key regulators of mineralisation. This study, therefore,
sought to examine the effect of a short-term continuous
PTH exposure on PHOSPHO1, TNAP and nSMase2
expression in osteoblast-like cells and calvariae explants as
well as to examine the PTH signal transduction pathways
involved.
Results
Temporal Gene and Protein Expression and Matrix
Mineralisation in MC3T3 Cells
MC3T3-C14 cells cultured in the presence of ascorbic acid
and calcium chloride mineralised their ECM by day 10.
Quantification of leached Alizarin red confirmed a signif-
icant increase in mineral content on day 10 compared with
day 7 of culture (0.775 ± 0.145 vs. 0.125 ± 0.01 relative
absorbance units, P\ 0.001; Fig. 1a, b). Phospho1 mRNA
expression markedly increased in a temporal manner and
by day 10 in culture mRNA levels were * 150-fold higher
(P\ 0.001) compared to day 0 (Fig. 1c). A similar tem-
poral increase in Alpl and Smpd3 was also noted and by day
10 in culture where the expression of both was increased by
[60-fold (P\ 0.001) compared to day 0 (Fig. 1d, e). The
changes in gene expression were similarly observed at the
protein level by western blotting (Fig. 1f). The expression
of both PHOSPHO1 protein bands, which are considered to
be a result of alternative start sites, was increased similarly
with time in culture [8].
The Effects of Continuous PTH on Matrix
Mineralisation in MC3T3 Cells
The addition of 50 nM PTH every 48 h to MC3T3-C14 cell
cultures for 10 days caused a reduction in the extent of
matrix mineralisation compared to control cultures as
assessed by the quantitative alizarin red assay (P\ 0.05;
Fig. 1g).
The Effects of Continuous PTH on Gene and Protein
Expression in MC3T3 Cells
Initial experiments assessed the ability of varying con-
centrations of PTH to regulate Phospho1, Alpl and Smpd3
expression by MC3T3-C14 cells. MC3T3-C14 cells were
treated with 0.05–50 nM PTH for 24 h on day 6 of culture,
when initial mineral formation could be observed with light
microscopy. At concentrations of 0.5 nM and above, PTH
significantly down-regulated Phospho1 mRNA expression
(P\ 0.001; Fig. 2a). PTH increased Alpl expression at the
two highest concentrations examined, 25 nM (P\ 0.05)
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Fig. 1 Extracellular matrix
mineralisation and temporal
gene expression in MC3T3-C14
cells. a Alizarin red staining and
b relative quantification of
cetylpyridinium chloride
leached bound dye. RT-qPCR
analysis of c Phospho1 d Alpl
and e Smpd3 mRNA expression
in mineralising MC3T3-C14
cells over a 10-day culture
period. f Western blotting
analysis of PHOSPHO1, TNAP
and nSMase2 in MC3T3-C14
cells over a 10-day culture
period. The fold change in
fluorescence intensity against
cultures at day 0 (normalised
against beta-actin) is shown
below each protein of interest.
g Assessment of matrix
mineralisation in MC3T3-C14
cell cultures continuously
exposed to PTH for 10 days.
Quantification of,
cetylpyridinium chloride
leached, bound Alizarin red
staining. N = 3; *P\ 0.05,
**P\ 0.01; ***P\ 0.001 in
comparison with the previous
time point in culture
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and 50 nM (P\ 0.001), whereas it down-regulated Smpd3
expression at all concentrations examined (P\ 0.001;
Fig. 2b, c). Western blotting confirmed that the changes in
gene expression were replicated at the protein level
(Fig. 2j).
We next examined the temporal effects of PTH on
Phospho1, Alpl and Smpd3 expression at day 7 of culture
(matching the end point in experiments described in
Fig. 2a–c). PTH rapidly down-regulated Phospho1 after
15 min which was further exacerbated after 1-h and 6-h
exposures (P\ 0.001; Fig. 2d). By 24 h, the down-regu-
lation of Phospho1 by PTH was lessened (P\ 0.05), and
after 48-h and 72-h exposures Phospho1 expression had
returned to basal levels (Fig. 2d). Enhancement of Alpl
expression by PTH was noted after 1 h (P\ 0.05), peaking
at 6 h (P\ 0.001) before returning to control levels after
24-h and longer exposures (Fig. 2e). The expression pat-
tern of Smpd3 in response to PTH was similar to that of
Phospho1; however, the speed of reduced expression and
its normalisation was slower (Fig. 2f). Changes in protein
levels of PHOSPHO1, TNAP and nSMase2 reflected their
respective changes in gene expression (Fig. 2k). Notably,
the expression levels of PHOSPHO1 and nSMase2 were
less, and TNAP was greater after 24-h and 48-h PTH
exposure (Fig. 2k). After a 72-h exposure all proteins were
expressed at a comparable level to the control treated
cultures.
Finally, the effect of PTH (50 nM, 24 h) on the
expression of Phospho1, Alp1 and Smpd3 was assessed in
MC3T3-C14 cells at different stages of differentiation.
Phospho1 and Smpd3 regulation by PTH was not depen-
dent on the differentiation status of the cell cultures, with
both genes significantly down-regulated (P\ 0.001) at 0, 7
and 10 days in culture (Fig. 2g, i). In contrast, PTH-in-
duced expression of Alpl was more restricted and only
reached significance at day 0 (P\ 0.01; Fig. 2h). Little or
no PHOSPHO1, nSMase2 or TNAP protein was expressed
at day 0 in culture, and this was not altered by PTH
treatment (Fig. 2l). At days 7 and 10, however, PTH
decreased PHOSPHO1 and nSMase2 expression whilst
increasing TNAP expression, consistent with the gene
expression data (Fig. 2l).
The Effects of Continuous PTH on Gene Expression
in Murine Calvariae
Murine hemi-calvariae were treated with 50 nM PTH for 2,
6 and 24 h. A significant downregulation of both Phospho1
and Smpd3 expression in response to PTH was observed at
2 h (P\ 0.05), 6 and 24 h (P\ 0.001; Fig. 3a, c). Like-
wise, continuous PTH exposure induced a down-regulation
of Alpl expression, albeit only with 24-h exposure
(P\ 0.01; Fig. 3b).
The Effects of Cycloheximide on PTH on Phospho1,
Alpl and Smpd3 Gene Regulation
To determine whether PTH directly regulates Phospho1,
Alpl and Smpd3 gene expression, MC3T3-C14 cells were
pre-treated for 1 h with the protein synthesis inhibitor
cycloheximide (25 lM), followed by treatment with
50 nM PTH for 6 h. Cycloheximide treatment alone did
not affect basal levels of Phospho1, Alpl or Smpd3. In the
presence of cycloheximide, PTH reduced the expression of
Phospho1 (44.1 %, P\ 0.01), but this was not to the same
extent observed in the absence of cycloheximide (93.9 %,
P\ 0.001; Fig. 4a). Cycloheximide treatment did not
affect the potent regulation of Alpl and Smpd3 expression
by PTH (Fig. 4b, c).
Identification of the Intracellular Signalling
Pathways Responsible for PTH Regulation
of Phospho1, Alpl and Smpd3 Expression
Binding of PTH to the G-protein-coupled receptor PTHR1
primarily activates cAMP/PKA and PKC signalling path-
ways [25]. To determine which of these pathways was
utilised by PTH to regulate Phospho1, Alpl and Smpd3
expression, we treated MC3T3-C14 cells and murine hemi-
calvariae with the cAMP inducer forskolin (10 lM) or the
PKC activator, PMA (100 nM) for 24 h. In MC3T3-C14
cells, forskolin replicated the effects of 50 nM PTH by
inducing significant decreases in Phospho1 (P\ 0.001)
and Smpd3 expression (P\ 0.001) whilst significantly
increasing the expression of Alpl (P\ 0.001) PMA treated
bFig. 2 Regulation of key mineralisation genes by PTH in MC3T3-
C14 cells. RT-qPCR analysis of a Phospho1, b Alpl and c Smpd3
mRNA expression in response to a 24-h exposure of various doses of
bPTH (1–34) on day 6 of culture. RT-qPCR analysis of d Phospho1,
e Alpl and f Smpd3 mRNA expression in response to various exposure
times of bPTH (1–34) (50 nM). The timing of PTH addition was
adjusted to ensure all experiments finished on day 7 of culture. RT-
qPCR analysis of g Phospho1, h Alpl and i Smpd3 mRNA expression
in response to 24-h exposure PTH (50 nM) in MC3T3-C14 cells at
different stages of differentiation (confluency (day 0), days 7 and day
10 post-confluency). j Western blotting analysis of PHOSPHO1,
TNAP, nSMase2 in response to a 24-h exposure of various doses of
PTH. The fold change in fluorescence intensity against control treated
cultures (normalised against beta-actin) is shown below each protein
of interest. k Western blotting analysis of PHOSPHO1, TNAP,
nSmase2 in response to various exposure times of PTH (50 nM). The
fold change in fluorescence intensity against control treated cultures
(normalised against beta-actin) is shown below each protein of
interest. l Western blotting analysis of PHOSPHO1, TNAP, nSMase2
in response a 24-h exposure PTH (50 nM) in MC3T3-C14 cells at
different stages of differentiation. The fold change in fluorescence
intensity against day 0 control treated cultures (normalised against
beta-actin) is shown below each protein of interest. N = 3;
*P\ 0.05; **P\ 0.01; ***P\ 0.001 in comparison with controls
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cells displayed no differences in Phospho1, Alpl or Smpd3
expression compared with control cultures (Fig. 5a–c). The
gene expression results in MC3T3-C14 cells were con-
firmed at the protein level by western blotting (Fig. 5d). In
hemi-calvariae, forskolin similarly replicated the effects of
50 nM PTH by inducing a significant decrease in Phospho1
(P\ 0.05) Smpd3 (P\ 0.001) Alpl (P\ 0.001) expres-
sion (Fig. 5e–g). PMA-treated hemi-calvariae displayed no
differences in Phospho1 expression; however, the expres-
sion of Alpl and Smpd3 was strongly down-regulated by
exposure to PMA (P\ 0.001). To confirm the role of the
PKA signalling pathway as the mediator of the effects of
PTH in MC3T3-C14 cells, cell cultures were treated with
the PKA inhibitor PKI (5-24) (100 nM) alone or in the
presence of PTH for 6 h. The addition of PKI (5-24) alone
did not alter the basal expression of Phospho1, Alpl or
Smpd3. The addition of the PKA inhibitor reduced the
ability of 50 nM PTH to significantly inhibit the expression
of Phospho1 and Smpd3 (Fig. 6a, c). Similarly, the
induction of Alpl expression by PTH was abrogated by the
co-incubation of PKI (5-24) (Fig. 6b). In cultured hemi-
calvariae, PKI (5-24) inhibited the down-regulation of
Phospho1 by PTH, whereas the down-regulation of Smpd3
by PTH was not affected by PKI (5-24) (P\ 0.001;
Fig. 6f).
Assessment of Transcription Factor Expression
in Response to PTH in Cultured MC3T3 Cells
and Murine Calvariae
The expression of the transcription factors Runx2, Sp7, Atf4
and Trps1 was assessed by RT-qPCR in MC3T3 cell cul-
tures and cultured murine calvariae in response to a short-
term PTH exposure. In MC3T3 cells, the expression of
Runx2 and Trps1 did not change in response to PTH
exposure (Fig. 7a, d). Sp7 expression was reduced after a
6-h PTH exposure (P\ 0.01; Fig. 7b), whereas Atf4 was
enhanced after 15-min PTH exposure (P\ 0.01; Fig. 7c).
In cultured murine calvariae, the expression of Runx2, Atf4
and Trps1 was not altered in response to PTH exposure
(Fig. 7e, g, h). Sp7 expression was significantly down-
regulated after a 2-h PTH exposure (P\ 0.05; Fig. 7f).
Fig. 3 Regulation of key mineralisation genes by PTH in cultured calvariae. RT-qPCR analysis of a Phospho1, b Alpl and c Smpd3 mRNA
expression in response to various exposure times of PTH (50 nM). N[ 3 per time point; *P\ 0.05; ***P\ 0.001 in comparison with control
Fig. 4 Effects of bPTH (1–34) on Phospho1, Alpl and Smpd3 in
MC3T3-C14 cells does not require protein synthesis. MC3T3-C14
cells were treated for 6 h with 50 nM PTH or vehicle control after a
2-h pre-treatment with 50 lM cycloheximide (CHX) or solvent
control on day 7 in culture. a Phospho1, b Alpl and c Smpd3 mRNA
expression was assessed by RT-qPCR. N = 3; *P\ 0.05;
**P\ 0.01; ***P\ 0.001 in comparison with vehicle control
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Investigating the Combined Effects of Continuous
PTH and BMP-2 Exposure on Gene Expression
in MC3T3 Cells
To investigate the effects of continuous PTH exposure in
MC3T3 cells treated with BMP-2, MC3T3 cell cultures
were cultured with either 50 nM PTH, 300 ng/mL BMP-2
or both for 24 h on day 6 of culture, and the expression of
Phospho1, Alpl and Smpd3 was assessed by RT-qPCR.
BMP-2 exposure significantly induced the expression of
Phospho1, Alpl and Smpd3 (P\ 0.001; Fig. 8a–c). The
stimulatory effect of BMP-2 on Phospho1 expression was
nullified by the dual exposure of PTH which caused
Phospho1 expression to return to unstimulated control
Fig. 5 Investigation of signalling pathways regulating the effects of
PTH. MC3T3-C14 cells were treated with 50 nM PTH, 25 lM
forskolin, 100 nM PMA or vehicle control for 24 h on day 6 in
culture. a Phospho1, b Alpl and c Smpd3 mRNA expression was
assessed by RT-qPCR. d Western Blotting analysis of MC3T3-C14
cells treated as described above. Hemi-calvariae were treated with
50 nM PTH, 25 lM forskolin, 100 nM PMA or vehicle control for
24 h. e Phospho1, f Alpl and g Smpd3 mRNA expression was
assessed by RT-qPCR. N = 3; *P\ 0.05; **P\ 0.01; ***P\ 0.001
in comparison with vehicle control
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levels (Fig. 8a). In contrast, the Smpd3 expression in cells
treated with PTH or PTH and BMP-2 was similar, sug-
gesting that Smpd3 expression was highly sensitive to PTH
exposure (P\ 0.001; Fig. 8c). The increased expression of
Alpl by BMP-2 was not affected by the co-incubation of
PTH.
Discussion
The role for TNAP in promoting ECM mineralisation has
long been recognised and more recent studies have also
identified PHOSPHO1 and nSMase2 as important regula-
tors of the biomineralisation process [7, 11, 26]. It is likely
that nSMase2 and PHOSPHO1 function together to control
the initiation of mineralisation via the liberation of Pi
within the sheltered confines of osteoblast and chondrocyte
MVs [1]. This possibility is supported by the observation
that both PHOSPHO1 and nSMase2 are present in MV’s
[27]. In contrast, TNAP is bound, by means of a
glycosylphosphatidylinositol anchor, to the outer leaflet of
MV membranes, whereby its pyrophosphatase activity
modulates the extravesicular Pi/PPi ratio so as to provide
an environment conducive to mineral propagation
[1, 11, 13]. The complete ablation of ECM mineralisation
noted in Phospho1-/-;Alpl-/- double-knockout mice
underscores the importance and the non-redundant func-
tions of these two phosphatases in regulating skeletal
mineralisation [11]. Recent studies have further shown that
MV’s initiate mineralisation by a dual mechanism:
PHOSPHO1-mediated intravesicular generation of Pi and
phosphate transporter-mediated influx of Pi [28]. Despite
knowledge of the function of these mineralisation-depen-
dant proteins, there exists a hiatus in the knowledge sur-
rounding their regulation. However, recent transcriptome
sequencing analysis revealed that Phospho1 is regulated by
PTH in osteocytes [16]. This study was the impetus for this
present investigation, where we sought to determine whe-
ther the catabolic effects of continuous PTH may be
attributed to the regulation of PHOSPHO1 expression by
Fig. 6 Inhibition of PKA signalling pathway abolishes the effects of
PTH (1–34). MC3T3-C14 cells and hemi-calvariae were treated with
50 nM PTH or vehicle control for 6 h following a 1-h pre-treatment
with 100 nM PKI (5–24) on day 6 of culture. a Phospho1, b Alpl and
c Smpd3 mRNA expression in MC3T3-C14 and d Phospho1, e Alpl
and f Smpd3 mRNA expression in hemi-calvariae, all assessed by RT-
qPCR. N = 3; *P\ 0.05; **P\ 0.01, ***P\ 0.001 in comparison
with vehicle control
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osteoblasts, and also how this regulation may be coordi-
nated with TNAP and nSMase2 expression.
This study has revealed that PHOSPHO1, nSMase2 and
TNAP display coordinated and significant increases in the
levels of transcript and protein prior to the onset of ECM
mineralisation in the MC3T3-C14 osteoblast-like cell line.
In particular, the similarities in the temporal rise of
PHOSPHO1 and nSMase2 protein bolster the idea that
these phosphatases work in tandem to generate Pi within
MV during the initiation of mineralisation. Furthermore,
PHOSPHO1 has recently been implicated in the biogenesis
of MV [28], and as such its expression prior to the onset of
mineralisation is crucial for the formation of MVs that
ultimately contain a precipitated carbonate-substituted
hydroxyapatitic mineral phase [29, 30]. The higher
expression of TNAP late on (day 10) noted in the time
course of this study, highlights its role in the later stages of
mineralisation where it allows the propagation of hydrox-
yapatite within the ECM beyond the confines of the MV
membrane [1, 10].
This study provides the first evidence for the potent
regulation of Phospho1 and Smpd3 by PTH in osteoblast-
Fig. 7 Transcription factor expression in response to short-term PTH
exposure. a Runx2, b Sp7, c Atf4 and d Trps1 mRNA expression was
assessed by RT-qPCR in MC3T3-C14 cell cultures in response to a
short-term exposure to 50 nM PTH on day 7 of culture. e Runx2,
f Sp7, g Atf4 and h Trps1 mRNA expression was assessed by RT-
qPCR in cultured murine calvariae in response to a short-term
exposure to 50 nM PTH. N = 3; *P\ 0.05; **P\ 0.01 in compar-
ison with control-treated cultures
Fig. 8 Combined effects of continuous PTH and BMP-2 exposure on
Phospho1, Alpl and Smpd3 expression in MC3T3-C14 cells. a Phos-
pho1, b Alpl and c Smpd3 mRNA expression was assessed by RT-
qPCR in MC3T3-C14 cell cultures in response to a 24 h exposure to
50 nM PTH, 300 ng/mL BMP-2 or both on day 6 of culture. N = 3;
*P\ 0.05; ***P\ 0.001 in comparison to control treated cultures;
###P\ 0.001 in comparison with BMP-2-treated cultures
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like cells and cultured calvariae. Our data build on previous
investigations which have sought to uncover the regulation
of mineralisation-dependent genes by growth factors and
hormones. The enhancement of nSMase2 expression by
BMP-2 signalling was recently reported in chondrocytes
and C2C12 myoblast cells [31, 32]. In this present study we
have confirmed and expanded these findings, by revealing
that continuous PTH exposure is able to significantly
down-regulate Smpd3 expression even in the presence of
BMP-2. Phospho1 expression was similarly enhanced by
BMP-2 exposure, with concomitant PTH exposure restor-
ing expression levels to those of control cultures. The
effects of BMP signalling on PHOSPHO1 regulation and
the interaction between BMP and PTH signalling are
intriguing and worthy of further investigation.
Whilst we found no interaction between PTH and BMP-
2 in the regulation of Alpl expression, the effects of PTH
alone on Alpl expression have been well documented. For
example, intermittent exposure to PTH has been shown to
stimulate ALP activity and bone nodule formation [33].
However, it should be noted that the inhibition of osteo-
blast differentiation by PTH has been reported in other
studies [34, 35], and this variation in response may be
explained by differences in osteoblast differentiation stage
and PTH exposure time and dosage. PTH can exert entirely
opposing effects on bone which depend upon the length of
exposure. Intermittent exposure to PTH is anabolic to the
skeleton, with reactivation of bone lining cells [36], inhi-
bition of osteoblast apoptosis [37] and down-regulation of
sclerostin, the potent negative regulator of Wnt signalling
and bone formation [38]. Currently, rhPTH (1-34) (Teri-
paratide) is the only anabolic therapy for osteoporosis
aimed at preventing both vertebral and non-vertebral
fractures in post-menopausal women [39]. Contrastingly,
continuous exposure to PTH, as observed in hyper-
parathyroidism, is catabolic to bone, increasing osteoclas-
togenesis through upregulation of RANKL and inhibition
of osteoprotegerin expression [22]. Knowledge of the
effects of continuous exposure to PTH is, however, limited
with regard to the regulation of mineralisation-promoting
enzymes despite an overall increase in the remodelling rate
observed in hyperparathyroidism [21]. The nature of the
PTH administration described in this study, whereby PTH
is added to the culture medium, and the medium is not
changed before the experiments are stopped for collection
of RNA/protein, which most closely resembles a continu-
ous exposure to PTH. Indeed a number of investigations to
date have demonstrated this method of PTH exposure to
better model the catabolic effects of PTH [40, 41]. With
bovine PTH (1-34) having a reported half-life of 10–12 h
in vitro a biologically effective dose of *3 nM should
have remained in our cultures after 48 h. However, as our
time exposure studies show (Fig. 2d–e), Phospho1 and Alpl
gene expression levels were normalised by 48 h. This
suggests the lack of a biologically effective dose of PTH at
this time point. In contrast, Smpd3 expression remained
significantly down-regulated at 48 h possibly reflecting the
increased sensitivity of this gene to PTH challenge
(Fig. 2f). These data bring into question the levels of bio-
logically active PTH remaining in our experimental cul-
tures and highlight the limitations of this approach.
However, this method of PTH exposure is in contrast to
in vitro studies which seek to model the effects of inter-
mittent PTH, whereby PTH is added to cell cultures for
1–6 h per 24-h or 48-h incubation cycle [40, 42]. The
findings presented here show for the first time that con-
tinuous administration of PTH to osteoblast cultures inhi-
bits the expression of Phospho1 and Smpd3.
The reduction of PHOSPHO1 and nSMase2 may pro-
vide a novel mechanism by which continuous PTH expo-
sure results in decreased bone mineral density. Indeed,
continuous exposure to PTH reduced the extent of matrix
mineralisation in MC3T3-C14 cell cultures (Fig. 1g) cor-
roborating existing reports which assessed this protocol in
rat calvarial osteoblast cultures [40]. Recent studies have
provided data which highlight a role for PHOSPHO1 and
nSMase2 in the biogenesis of matrix vesicles [28, 43, 44].
It is possible, therefore, that the reduced mineralisation of
MC3T3-C14 cell cultures observed in response to contin-
uous exposure to PTH is due to both a decreased number of
MVs being released and a decrease in their ability to ini-
tiate amorphous hydroxyapatite formation. Despite this,
Alpl expression was induced in response to PTH in
MC3T3-C14 cell cultures. An enhancement of Alpl
expression and TNAP activity in response to a continuous
exposure to PTH has previously been shown in periodontal
ligament cells [45] and in the UMR-106 cell line [46],
respectively. Even with this body of evidence in mind, the
differential regulation of Phospho1 and Alpl by PTH is
perhaps surprising. The genetic ablation of Phospho1 in the
mouse leads to reduced serum TNAP activity and reduced
Alpl expression in cultured chondrocytes derived from
these mice [11]. Importantly, cultured hemi-calvariae
exposed to continuous PTH exposure for 24 h displayed a
down-regulation of Alpl expression (Fig. 3b). The ex vivo
culture of calvariae may provide a more physiologically
relevant model of osteoblast behaviour due to the mainte-
nance of both cell–cell and cell–matrix interactions in
three-dimensional space.
To enact its effects, PTH binds to the PTH 1 receptor
(PTH1R), a G-protein-coupled receptor, through a receptor
binding domain between amino acids 15–24 [47]. Both
PKA and PKC signal transduction pathways may be acti-
vated by binding of PTH to PTH1R. The effects of PTH are
primarily elicited through the PKA pathway whereby,
stimulatory Gas proteins activate adenylate cyclase, with
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subsequent production of cAMP and phosphorylation of
PKA [17]. A limited number of genes, for example those
encoding the insulin-like growth-factor-binding protein 5
and transforming growth factor b1, have been found to be
regulated by Gaq activation, which results in PKC acti-
vation, 1,4,5-inositol triphosphate production and a rise in
intracellular Ca2? [25]. A critical role for the cAMP-PKA
pathway in mediating the effects of PTH on PHOSPHO1,
nSMase2 and TNAP expression in osteoblast cell cultures
model has been revealed in this study. Firstly, the adenylyl
cyclase agonist, forskolin, replicated the effects of PTH,
whereas exposure to the PKC agonist, PMA, caused no
effects. Furthermore, specific inhibition of the cAMP
activation of PKA by the synthetic peptide PKI (5-24)
abrogated the effects of PTH on Phospho1, Alpl and Smpd3
expression (Fig. 9). In support of a role for PKA signalling
in the downregulation of the mineralisation-dependent
enzymes, PHOSPHO1 and nSMase2, studies to date have
shown the inhibition of both MC3T3-E1 matrix minerali-
sation and bone nodule formation by cultured rat calvarial
cells with long-term exposure to forskolin [48, 49]. Our
studies involving cycloheximide reveal that this genetic
regulation is not dependent on protein synthesis. It is noted
that cycloheximide appeared to partially affect the down-
regulation of Phospho1 by PTH exposure (inducing a
49.5 % decrease as opposed to a 93.9 % decrease by PTH
alone). Despite this, it is well accepted that cycloheximide
can exert off-target effects [50], and these may account for
this difference. Finally, we assessed the expression of the
osteogenic transcription factors Runx2, Sp7 and Atf4 and
Trps1, which has recently been implicated in the regulation
of Phospho1 in a preodontoblastic cell line [51]. In both
cultured murine calvariae and MC3T3-C14 cells, Sp7
expression was reduced in response to PTH. This suggests
that osterix (encoded by the Sp7 gene), one of the master
transcription factors regulating osteogenic differentiation,
may be an important transcription factor in the regulation
of both Phospho1 and/or Smpd3 expression. The study of
the transcriptional and epigenetic regulation of these min-
eralisation-dependent genes requires further study, and it is
of interest to note that Runx2 overexpression in mouse
limb bud cells has been shown to result in elevated
expression of both Phospho1 and Smpd3 [52].
These data are novel for the PTH control of Phospho1
and Smpd3 expression, but previous reports have demon-
strated the involvement of the cAMP-PKA pathway in the
regulation (both positive and negative) of TNAP activity in
a variety of cell culture models of mineralisation
[33, 40, 45, 46]. The PTH-dependent enhancement of
TNAP activity has been shown to be enacted through
Fig. 9 Schematic representation of the signalling pathways mediat-
ing PTH and BMP-2 induced regulation of Phospho1, Smpd3 and Alpl
in osteoblast cells. Recapitulation of the effects of PTH, through the
use of the cAMP agonist, forskolin, and inhibition of the effects of
PTH through the use of the PKA inhibitor, PKI (5–24) have
implicated the cAMP/PKA pathway in mediating the down-regulation
of Phospho1 and Smpd3, and the enhancement of Alpl mRNA
expression in response to PTH treatment. Initial studies have
identified BMP-2 as an inducer of Phospho1, Smpd3 and Alpl
expression, although the intracellular signalling pathway is yet to be
elucidated. PTH, parathyroid hormone; PTH1R, parathyroid hormone
receptor 1; AC, adenylyl cyclase; ATP, adenosine triphosphate;
cAMP, cyclic adenosine monophosphate; PKA, protein kinase A;
BMP2, bone morphogenic protein 2; BMPR1A, bone morphogenic
protein receptor 1A
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cAMP-PKA-mediated activation of p38 MAP kinase [53].
In the cultured hemi-cavariae experiments, cAMP stimu-
lation by forskolin simulated the effects of PTH by
inducing a downregulation of Phospho1, Alpl and Smpd3.
In contrast to MC3T3-C14 cell cultures, however, PMA
similarly induced the down-regulation of Alpl and Smpd3,
and blockade of PKA activation by PKI (5-24) did not
affect the PTH-induced downregulation of Smpd3. To date,
Phospho1 has been shown to be exclusively expressed by
osteoblasts, hypertrophic chondrocytes, odontoblasts and
calcifying vascular smooth muscle cells [8, 9, 54]. Smpd3
and Alpl, on the other hand, are more broadly expressed
amongst different tissues and cell types. Although provid-
ing a more physiological environment, the presence of
osteocytes, osteoclasts and stromal cells, as well as osteo-
blasts at differing stages of development in the ex vivo
calvariae model, may be confounding our investigation of
the signalling pathways in this model.
In summary, the data presented here provide evidence
for of a temporal rise in the expression of key minerali-
sation effector enzymes, PHOSPHO1, TNAP and
nSMase2, prior to the onset of in vitro mineralisation. This
finding highlights the importance of these enzymes in this
process. Furthermore, the potent negative regulation of
Phospho1 and Smpd3 by continuous exposure to PTH may
provide an additional means of explaining the poor bone
quality observed in response to sustained and elevated
exposures to PTH.
Materials and Methods
MC3T3-Clone 14 Cell Culture
MC3T3 subclone 14 cells (MC3T3-C14) (ATCC, CRL-
2594TM) previously characterised as a highly mineralising
clone of the MC3T3-E1 cell line [13, 55] were plated at
1 9 104 cells/cm2 in six-well plates and cultured in
maintenance medium (a-MEM containing 10 % FBS and
0.5 % Gentamicin) (Invitrogen, Paisley, UK) in a humidi-
fied atmosphere (37 C, 5 % CO2). Upon confluency,
maintenance media was replaced with mineralisation
media (maintenance medium supplemented with 50 lg/ml
L-ascorbic acid and 1.5 mM calcium chloride) (Sigma-
Aldrich, Dorset, UK). Supplementation with calcium
chloride successfully induces ECM mineralisation and
negates the need for exogenous phosphate sources (e.g.
beta-glycerophosphate) and therefore potential ectopic
mineralisation or enhanced induction of Alpl expression
[13, 56, 57]. Media was changed every 2–3 days for up to
10 days.
To examine the effects of continuous exposure of PTH
on MC3T3-C14 gene and protein expression, the media
was replaced with fresh mineralisation media containing
either bPTH (1-34) (Sigma-Aldrich) (referred to as PTH) at
various concentrations (0.5–50 nM) or vehicle (PBS) and
for various lengths of time (15 min–72 h). Unless other-
wise stated, cells were cultured for 6 days (from conflu-
ency) under osteogenic conditions prior to the addition of
PTH in order to avoid suppression of osteoblast differen-
tiation [58, 59]. In experiments utilising BMP-2, cell cul-
tures were treated with recombinant human BMP-2
(300 ng/mL; R & D Systems, Abingdon, UK) for 24 h. To
investigate the signalling pathways mediating the effects of
PTH, cells were also treated with forskolin (25 lM; Sigma-
Aldrich), phorbol 12-myristate 13-acetate (PMA, 100 nM;
Sigma-Aldrich), and PKI (5-24) (100 nM; Santa Cruz
Biotechnology, Texas, USA) or appropriate vehicle con-
trols for the time indicated. To assess the requirement of
protein synthesis in the PTH regulation of Phospho1, Alpl
and Smpd3, cells were pre-incubated for 2 h with cyclo-
heximide (25 lM; Sigma-Aldrich) or DMSO control prior
to stimulation with either 50 nM PTH or PBS for 6 h.
Murine Calvariae Culture
Calvariae from 4- to 5-day-old C57Bl/6 J pups were dis-
sected under sterile conditions. Hemi-calvariae were
formed by cutting along the sagittal suture of the calvaria.
Hemi-calvariae were cultured in 24-well plates in 350 lL
of calvaria culture medium (a-MEM containing 0.2 % w/v
bovine serum albumin, 0.05 mg/ml gentamicin, 1.25 lg/
mL Amphotericin B and 5 lg/ml L-ascorbic acid). After
24 h hemi-calvariae were treated with 50 nM PTH, for-
skolin (25 lM), PMA (100 nM) and PKI (5-24) (100 nM)
for the times indicated.
Quantification of Extracellular Matrix
Mineralisation
The effect of continuous PTH exposure on the ECM
mineralisation of MC3T3-C14 cells was assessed by ali-
zarin red staining and quantification. To examine the
effects of continuous PTH on the ECM mineralisation, cell
cultures were exposed to either 50 nM PTH or PBS control
for 10 days under osteogenic conditions; media changes,
including fresh PTH or control, were performed every
48 h. On day 10 of culture, cells cultures were fixed in 4 %
paraformaldehyde for 5 min at room temperature. Cell
monolayers were stained with aqueous 2 % (w/v) Alizarin
red solution (Sigma-Aldrich) for 5 min at room tempera-
ture. The bound stain was solubilised in 10 % cetylpyri-
dinium chloride (Sigma-Aldrich) and the optical density of
the resultant eluted solution measured by spectrophotom-
etry at 570 nm.
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Analysis of Gene Expression by Quantitative Real-
Time PCR
MC3T3-C14 cultures and hemi-calvariae were stopped at
the desired time in culture and total RNA was extracted
using the RNeasy mini kit and RNeasy mini lipid kit,
respectively, (Qiagen, Crawley, UK) according the manu-
facturer’s instructions. RNA concentration was assessed by
absorbance at 260 nm and purity by A260/280 ratio using a
NanoDrop spectrophotometer (Fisher Scientific, Lough-
borough, UK). Reverse transcription of RNA was carried
out using Superscript II (Invitrogen) according to the
manufacturer’s instructions. Gene expression analysis,
using the SYBR green detection method was performed on
a Stratagene Mx3000P real-time qPCR system (Stratagene,
California, USA). Samples were assessed in triplicate and
normalised against the house keeping gene, Atp5b (Primer
Design, Southampton, UK) as previously done in similar
studies [13]. Relative gene expression was calculated using
the DDCt method [60] and expressed as a fold change
compared to control. The primers used to amplify Phos-
pho1, Smpd3, Alpl, Runx2, Sp7, Atf4 and Trps1 are shown
in Table 1.
Western Blotting
Protein was extracted from cell monolayers using RIPA
buffer (Invitrogen) with complete protease inhibitors
(Roche, East-Sussex, UK). The concentration of the
resultant protein lysates was determined by DC assay (Bio-
Rad, Hemel Hempstead, UK). Proteins (10 lg) were sep-
arated on a 10 % Bis–Tris gel and transferred to a nitro-
cellulose membrane. Membranes were blocked with
Odyssey blocking buffer (LI-COR Biosciences, Nebraska,
USA) for 1 h at room temperature and probed overnight at
4 C with anti-PHOSPHO1 (AbD Serotec, Martinsreid/
Planegg, Germany), anti-TNAP (R&D, Abingdon, UK),
anti-nSMase2 (Santa Cruz Biotechnology) and anti-b-actin
(Cell Signalling Technology, Hitchin, UK) antibodies
diluted 1:1000, 1:500, 1:500 and 1:1000 respectively in
Odyssey blocking buffer with 1.875 % Tween 20. After
washing in PBS, membranes were probed with the appro-
priate secondary antibodies for 50 min at room temperature
(1:1250 dilution in Odyssey blocking buffer). The resulting
blots were subsequently washed in PBS and visualised
using the LI-COR Odyssey infrared scanner and software
(LI-COR biosciences) with a scan resolution of 169 lm.
Quantification of the fluorescence of each protein of
interest was performed using Image Studio Lite version 5.0
(LI-COR biosciences) and normalised against beta-actin.
The resulting quantification was expressed as fold change
compared with control-treated samples.
Statistical Analysis
Data analysis was performed using GraphPad Prism 6
(GraphPad Prism Inc., California, USA), and data are
presented as mean ± S.E.M. Comparisons between data-
sets were carried out using ANOVA or two-way ANOVA
with post hoc Tukey’s tests where appropriate. P\ 0.05
was considered to be significant and noted as ‘*’; P values
of\ 0.01 and\ 0.001 were noted as ‘**’ and ‘***,’
respectively.
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